Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.52 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.52 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 2/20 | 0.50 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | HRH2 | P25021 | 1/20 | 0.50 |
| ▸ | HTR1B | P28222 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12719189 | 0.86 | KMT2A (0.61) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL1488412 | 0.85 | KMT2A (0.60) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL14734421 | 0.85 | MEN1 (0.57) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL15067221 | 0.83 | MEN1 (0.61) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL324086 | 0.82 | TMEM97 (0.64) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL15499538 | 0.82 | KMT2A (0.60) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL23219629 | 0.82 | NPC1 (0.53) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL1489028 | 0.81 | KMT2A (0.59) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL3970912 | 0.80 | MEN1 (0.76) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL4814264 | 0.80 | MEN1 (0.76) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2001891-B1 | BUPRENORPHINE DERIVATIVES AND USES THEREOF | RB PHARMACEUTICALS LTD (GB) | 2013-07-24 | — | — | EP | disclosed |
| US-7964610-B2 | Buprenorphine derivatives and uses thereof | RECKITT BENCKISER HEALTHCARE (UK) LIMITED (GB) | 2011-06-21 | — | — | US | disclosed |
| US-20100234412-A1 | Buprenorphine Derivatives and Uses Thereof | RECKITT BENCKISER HEALTHCARE (UK) LIMITED (GB) | 2010-09-16 | — | — | US | disclosed |
| EP-2001891-A1 | BUPRENORPHINE DERIVATIVES AND USES THEREOF | Reckitt Benckiser Healthcare (UK) Limited (GB) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007110636-A1 | BUPRENORPHINE DERIVATIVES AND USES THEREOF | RECKITT BENCKISER HEALTHCARE (UK) LIMITED (GB) | 2007-10-04 | — | — | WO | disclosed |
| EP-1137640-B1 | CYCLIC HYDRAZINE DERIVATIVES AS TNF-ALPHA INHIBITORS | HOFFMANN LA ROCHE (CH) | 2005-09-21 | — | — | EP | disclosed |
| EP-1137640-A1 | CYCLIC HYDRAZINE DERIVATIVES AS TNF-ALPHA INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-04 | — | — | EP | disclosed |
| US-6281363-B1 | ANTIINFLAMMATORY AGENTS; ANTIARTHRITIC AGENTS; AUTOIMMUNE DISORDERS | HOFFMANN-LA ROCHE INC. | 2001-08-28 | — | — | US | disclosed |
| WO-2000035885-A1 | CYCLIC HYDRAZINE DERIVATIVES AS TNF-ALPHA INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-22 | — | — | WO | disclosed |
| US-4596791-A | Containing heterocyclic fused ring | USV PHARMACEUTICAL CORP. (US) | 1986-06-24 | — | — | US | disclosed |
| EP-0121830-A2 | Substituted dipeptides as antihypertensives | USV PHARMACEUTICAL CORPORATION (US) | 1984-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234412-A1 | Buprenorphine Derivatives and Uses Thereof | OPRD1, OPRK1, OPRM1 | MEN1 4882/4885KMT2A 1642/4885NPSR1 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.